Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.60 |
| ▸ | HRH2 | P25021 | 14/20 | 0.60 |
| ▸ | HRH1 | P35367 | 14/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619064 | 0.94 | HRH3 (0.70) | HRH3HRH2HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL1619076 | 0.92 | HRH3 (0.68) | HRH3HRH2HRH1KCNH2 | |
| SCHEMBL2966798 | 0.90 | KCNH2 (0.53) | HRH3HRH2HRH1KCNH2KCNA5 | |
| SCHEMBL2956719 | 0.85 | KCNA5 (0.53) | HRH3HRH2HRH1KCNH2KCNA5 | |
| SCHEMBL6093646 | 0.85 | HRH3 (0.81) | HRH3HRH2HRH1KCNA5 | |
| SCHEMBL3119483 | 0.84 | KCNH2 (0.52) | HRH3HRH2HRH1KCNH2KCNA5 | |
| SCHEMBL2964313 | 0.83 | HRH3 (0.43) | HRH3HRH2HRH1KCNH2 | |
| SCHEMBL2967582 | 0.83 | KCNH2 (0.52) | HRH3HRH2HRH1KCNH2KCNA5 | |
| SCHEMBL4509459 | 0.83 | HRH3 (0.48) | HRH3HRH2HRH1KCNH2 | |
| SCHEMBL15163479 | 0.82 | HRH3 (0.44) | HRH3HRH2HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7648985-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-7351821-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, SODERTALJE, SWEDEN | 2007-05-24 | — | — | US | disclosed |
| EP-1559717-A2 | Oxabispidine compounds useful in the treatment of cardiac arrythmias | AstraZeneca AB (SE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| EP-1307449-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002012235-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | HRH3 936/4885HRH2 680/4885HRH1 765/4885 |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 437/4885HRH2 616/4885HRH1 650/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | HRH3 817/4885HRH2 1257/4885HRH1 970/4885 |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | HRH3 6/4885HRH2 4/4885HRH1 5/4885 |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 420/4885HRH2 556/4885HRH1 591/4885 |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | HRH3 448/4885HRH2 521/4885HRH1 484/4885 |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 437/4885HRH2 616/4885HRH1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.